Aimmune Therapeutics (NASDAQ:AIMT) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Monday.
According to Zacks, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. “
A number of other research firms also recently issued reports on AIMT. BidaskClub upgraded shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, December 27th. Wedbush restated an “outperform” rating and set a $70.00 target price on shares of Aimmune Therapeutics in a research report on Friday, December 1st. ValuEngine downgraded shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Piper Jaffray Companies boosted their target price on shares of Aimmune Therapeutics from $38.00 to $60.00 and gave the company an “overweight” rating in a research report on Tuesday, December 5th. Finally, Robert W. Baird began coverage on shares of Aimmune Therapeutics in a report on Wednesday, December 20th. They issued an “outperform” rating and a $64.00 price objective for the company. Two analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $55.43.
Aimmune Therapeutics (NASDAQ:AIMT) last posted its earnings results on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.09. analysts expect that Aimmune Therapeutics will post -2.51 EPS for the current year.
In other Aimmune Therapeutics news, insider Douglas T. Sheehy sold 1,905 shares of Aimmune Therapeutics stock in a transaction on Thursday, November 9th. The shares were sold at an average price of $33.00, for a total value of $62,865.00. Following the completion of the transaction, the insider now owns 1,905 shares of the company’s stock, valued at $62,865. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Douglas T. Sheehy sold 47,425 shares of Aimmune Therapeutics stock in a transaction on Monday, October 23rd. The shares were sold at an average price of $34.44, for a total transaction of $1,633,317.00. Following the completion of the transaction, the insider now directly owns 34,300 shares of the company’s stock, valued at approximately $1,181,292. The disclosure for this sale can be found here. Insiders sold 136,298 shares of company stock valued at $4,929,669 in the last ninety days. 17.59% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. GSA Capital Partners LLP purchased a new position in Aimmune Therapeutics in the second quarter valued at $442,000. Point72 Asset Management L.P. increased its holdings in Aimmune Therapeutics by 10.2% in the third quarter. Point72 Asset Management L.P. now owns 1,098,087 shares of the biotechnology company’s stock valued at $27,222,000 after buying an additional 101,855 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in Aimmune Therapeutics by 139.9% in the second quarter. Goldman Sachs Group Inc. now owns 227,377 shares of the biotechnology company’s stock valued at $4,675,000 after buying an additional 132,603 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Aimmune Therapeutics by 16.9% during the second quarter. Bank of New York Mellon Corp now owns 131,353 shares of the biotechnology company’s stock worth $2,700,000 after purchasing an additional 19,016 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new stake in shares of Aimmune Therapeutics during the second quarter worth about $360,000. 73.34% of the stock is owned by institutional investors.
WARNING: This news story was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.com-unik.info/2018/01/08/aimmune-therapeutics-aimt-rating-lowered-to-sell-at-zacks-investment-research.html.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Aimmune Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aimmune Therapeutics and related companies.